Recent News

• 12.12.2025 - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
• 12.11.2025 - BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
• 11.12.2025 - BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 11.21.2025 - 8-K Current report
• 11.17.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.12.2025 - 8-K Current report
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - EX-99.1 EX-99.1
• 10.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities